- Home
- ENGN vs TECX Comparison
ENGN vs TECX Comparison
Compare ENGN & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ENGN | TECX |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.3M | 359.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ENGN | TECX |
|---|---|---|
| Price | $9.45 | $21.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $22.71 | ★ $81.20 |
| AVG Volume (30 Days) | 277.9K | ★ 336.4K |
| Earning Date | 12-22-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.65 | $13.70 |
| 52 Week High | $11.14 | $61.07 |
Technical Indicators
Market Signals| Indicator | ENGN | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 64.19 | 61.57 |
| Support Level | $7.57 | $17.79 |
| Resistance Level | $8.47 | $19.12 |
| Average True Range (ATR) | 0.73 | 1.24 |
| MACD | 0.10 | 0.17 |
| Stochastic Oscillator | 74.31 | 95.25 |
Price Performance
Historical ComparisonAbout ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About TECX Tectonic Therapeutic Inc.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.